ID   SOCS3_RAT               Reviewed;         225 AA.
AC   O88583; Q9QYV5;
DT   16-APR-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1998, sequence version 1.
DT   24-JUL-2024, entry version 152.
DE   RecName: Full=Suppressor of cytokine signaling 3 {ECO:0000305};
DE            Short=SOCS-3;
DE   AltName: Full=Cytokine-inducible SH2 protein 3;
GN   Name=Socs3 {ECO:0000312|RGD:621087}; Synonyms=Cish3;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Liver;
RX   PubMed=10579313; DOI=10.1210/endo.140.12.7212;
RA   Mao Y., Ling P.R., Fitzgibbons T.P., McCowen K.C., Frick G.P.,
RA   Bistrian B.R., Smith R.J.;
RT   "Endotoxin-induced inhibition of growth hormone receptor signaling in rat
RT   liver in vivo.";
RL   Endocrinology 140:5505-5515(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=Sprague-Dawley;
RA   le Cam A.;
RL   Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   INTERACTION WITH LEPTIN.
RX   PubMed=11108838; DOI=10.1016/s0014-5793(00)02205-5;
RA   Eyckerman S., Broekaert D., Verhee A., Vandekerckhove J., Tavernier J.;
RT   "Identification of the Y985 and Y1077 motifs as SOCS3 recruitment sites in
RT   the murine leptin receptor.";
RL   FEBS Lett. 486:33-37(2000).
CC   -!- FUNCTION: SOCS family proteins form part of a classical negative
CC       feedback system that regulates cytokine signal transduction. SOCS3 is
CC       involved in negative regulation of cytokines that signal through the
CC       JAK/STAT pathway. Inhibits cytokine signal transduction by binding to
CC       tyrosine kinase receptors including IL6ST/gp130, LIF, erythropoietin,
CC       insulin, IL12, GCSF and leptin receptors. Binding to JAK2 inhibits its
CC       kinase activity and regulates IL6 signaling. Suppresses fetal liver
CC       erythropoiesis. Regulates onset and maintenance of allergic responses
CC       mediated by T-helper type 2 cells (By similarity). Probable substrate
CC       recognition component of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-box
CC       protein) E3 ubiquitin-protein ligase complex which mediates the
CC       ubiquitination and subsequent proteasomal degradation of target
CC       proteins (By similarity). {ECO:0000250|UniProtKB:O14543,
CC       ECO:0000250|UniProtKB:O35718}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with multiple activated proteins of the tyrosine
CC       kinase signaling pathway including IGF1 receptor, insulin receptor and
CC       JAK2. Binding to JAK2 is mediated through the KIR and SH2 domains to a
CC       phosphorylated tyrosine residue within the JAK2 JH1 domain. Binds
CC       specific activated tyrosine residues of the leptin, EPO, IL12, GSCF and
CC       gp130 receptors. Interaction with CSNK1E stabilize SOCS3 protein.
CC       Component of the probable ECS(SOCS3) E3 ubiquitin-protein ligase
CC       complex which contains CUL5, RNF7/RBX2, Elongin BC complex and SOCS3.
CC       Interacts with CUL5, RNF7, ELOB and ELOC. Interacts with FGFR3 (By
CC       similarity). Interacts with INSR (By similarity). Interacts with BCL10;
CC       this interaction may interfere with BCL10-binding with PELI2 (By
CC       similarity). Interacts with NOD2 (via CARD domain); the interaction
CC       promotes NOD2 degradation (By similarity).
CC       {ECO:0000250|UniProtKB:O14543, ECO:0000250|UniProtKB:O35718,
CC       ECO:0000269|PubMed:11108838}.
CC   -!- DOMAIN: The ESS and SH2 domains are required for JAK phosphotyrosine
CC       binding. Further interaction with the KIR domain is necessary for
CC       signal and kinase inhibition.
CC   -!- DOMAIN: The SOCS box domain mediates the interaction with the Elongin
CC       BC complex, an adapter module in different E3 ubiquitin ligase
CC       complexes. {ECO:0000250}.
CC   -!- PTM: Phosphorylated on tyrosine residues after stimulation by the
CC       cytokines, IL-2, EPO or IGF1. {ECO:0000250}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF075383; AAC26223.1; -; mRNA.
DR   EMBL; AJ249240; CAB56083.1; -; Genomic_DNA.
DR   RefSeq; NP_446017.1; NM_053565.1.
DR   AlphaFoldDB; O88583; -.
DR   BMRB; O88583; -.
DR   SMR; O88583; -.
DR   BioGRID; 250151; 1.
DR   STRING; 10116.ENSRNOP00000003940; -.
DR   PhosphoSitePlus; O88583; -.
DR   PaxDb; 10116-ENSRNOP00000003940; -.
DR   GeneID; 89829; -.
DR   KEGG; rno:89829; -.
DR   UCSC; RGD:621087; rat.
DR   AGR; RGD:621087; -.
DR   CTD; 9021; -.
DR   RGD; 621087; Socs3.
DR   eggNOG; KOG4566; Eukaryota.
DR   InParanoid; O88583; -.
DR   OrthoDB; 5362214at2759; -.
DR   PhylomeDB; O88583; -.
DR   Reactome; R-RNO-1059683; Interleukin-6 signaling.
DR   Reactome; R-RNO-877300; Interferon gamma signaling.
DR   Reactome; R-RNO-877312; Regulation of IFNG signaling.
DR   Reactome; R-RNO-8849474; PTK6 Activates STAT3.
DR   Reactome; R-RNO-8951664; Neddylation.
DR   Reactome; R-RNO-909733; Interferon alpha/beta signaling.
DR   Reactome; R-RNO-9705462; Inactivation of CSF3 (G-CSF) signaling.
DR   Reactome; R-RNO-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   UniPathway; UPA00143; -.
DR   PRO; PR:O88583; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; ISO:RGD.
DR   GO; GO:0005942; C:phosphatidylinositol 3-kinase complex; IBA:GO_Central.
DR   GO; GO:0046935; F:1-phosphatidylinositol-3-kinase regulator activity; IBA:GO_Central.
DR   GO; GO:0035198; F:miRNA binding; ISO:RGD.
DR   GO; GO:0001784; F:phosphotyrosine residue binding; ISO:RGD.
DR   GO; GO:0030292; F:protein tyrosine kinase inhibitor activity; ISO:RGD.
DR   GO; GO:0031100; P:animal organ regeneration; IEP:RGD.
DR   GO; GO:0060670; P:branching involved in labyrinthine layer morphogenesis; ISO:RGD.
DR   GO; GO:0030154; P:cell differentiation; ISO:RGD.
DR   GO; GO:0007259; P:cell surface receptor signaling pathway via JAK-STAT; IDA:RGD.
DR   GO; GO:0097398; P:cellular response to interleukin-17; ISO:RGD.
DR   GO; GO:1990830; P:cellular response to leukemia inhibitory factor; ISO:RGD.
DR   GO; GO:1905229; P:cellular response to thyrotropin-releasing hormone; IEP:RGD.
DR   GO; GO:0071346; P:cellular response to type II interferon; IEP:RGD.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:RGD.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; ISO:RGD.
DR   GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; ISO:RGD.
DR   GO; GO:0046426; P:negative regulation of receptor signaling pathway via JAK-STAT; ISO:RGD.
DR   GO; GO:0009968; P:negative regulation of signal transduction; ISO:RGD.
DR   GO; GO:0042532; P:negative regulation of tyrosine phosphorylation of STAT protein; ISO:RGD.
DR   GO; GO:0046854; P:phosphatidylinositol phosphate biosynthetic process; IBA:GO_Central.
DR   GO; GO:0060674; P:placenta blood vessel development; ISO:RGD.
DR   GO; GO:0045597; P:positive regulation of cell differentiation; ISO:RGD.
DR   GO; GO:0016567; P:protein ubiquitination; IEA:UniProtKB-UniPathway.
DR   GO; GO:0001558; P:regulation of cell growth; TAS:RGD.
DR   GO; GO:0001932; P:regulation of protein phosphorylation; ISO:RGD.
DR   GO; GO:0009617; P:response to bacterium; IEP:RGD.
DR   GO; GO:0034097; P:response to cytokine; IEP:RGD.
DR   GO; GO:0032355; P:response to estradiol; IEP:RGD.
DR   GO; GO:0032094; P:response to food; IEP:RGD.
DR   GO; GO:0010332; P:response to gamma radiation; IEP:RGD.
DR   GO; GO:0051384; P:response to glucocorticoid; IEP:RGD.
DR   GO; GO:0009725; P:response to hormone; IEP:RGD.
DR   GO; GO:0001666; P:response to hypoxia; IEP:RGD.
DR   GO; GO:0032868; P:response to insulin; IEP:RGD.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEP:RGD.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEP:RGD.
DR   GO; GO:0043434; P:response to peptide hormone; IEP:RGD.
DR   GO; GO:0032570; P:response to progesterone; IEP:RGD.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEP:RGD.
DR   GO; GO:0007165; P:signal transduction; ISO:RGD.
DR   CDD; cd10384; SH2_SOCS3; 1.
DR   CDD; cd03737; SOCS_SOCS3; 1.
DR   Gene3D; 3.30.505.10; SH2 domain; 1.
DR   Gene3D; 1.10.750.20; SOCS box; 1.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR035863; SOCS3_SH2.
DR   InterPro; IPR028414; SOCS3_SOCS_box.
DR   InterPro; IPR001496; SOCS_box.
DR   InterPro; IPR036036; SOCS_box-like_dom_sf.
DR   PANTHER; PTHR10155; PHOSPHATIDYLINOSITOL 3-KINASE REGULATORY SUBUNIT; 1.
DR   PANTHER; PTHR10155:SF11; SUPPRESSOR OF CYTOKINE SIGNALING 3; 1.
DR   Pfam; PF00017; SH2; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00253; SOCS; 1.
DR   SMART; SM00969; SOCS_box; 1.
DR   SUPFAM; SSF55550; SH2 domain; 1.
DR   SUPFAM; SSF158235; SOCS box-like; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50225; SOCS; 1.
PE   1: Evidence at protein level;
KW   Growth regulation; Phosphoprotein; Reference proteome; SH2 domain;
KW   Signal transduction inhibitor; Ubl conjugation pathway.
FT   CHAIN           1..225
FT                   /note="Suppressor of cytokine signaling 3"
FT                   /id="PRO_0000181245"
FT   DOMAIN          46..142
FT                   /note="SH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          177..224
FT                   /note="SOCS box"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00194"
FT   REGION          22..33
FT                   /note="Kinase inhibitory region (KIR)"
FT   REGION          34..45
FT                   /note="Extended SH2 subdomain (ESS)"
FT   REGION          141..160
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   CONFLICT        75
FT                   /note="D -> G (in Ref. 2; CAB56083)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        85
FT                   /note="E -> K (in Ref. 2; CAB56083)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        145
FT                   /note="F -> S (in Ref. 2; CAB56083)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        164
FT                   /note="A -> G (in Ref. 2; CAB56083)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   225 AA;  24808 MW;  BC95FF2074125D8F CRC64;
     MVTHSKFPAA GMSRPLDTSL RLKTFSSKSE YQLVVNAVRK LQESGFYWSA VTGGEANLLL
     SAEPAGTFLI RDSSDQRHFF TLSVETQSGT KNLRIQCEGG SFSLQSDPRS TQPVPRFDCV
     LKLVHHYMPP PGAPSFSLPP TEPSFEVQEQ PPAQALPGGT PKRAYYIYSG GEKIPLVLSR
     PLSSNVATLQ HLCRKTVNGH LDSYEKVTQL PGPIREFLDQ YDAPL
//
